The Coalition for Aligning Science (CAS) designs and manages large-scale biomedical research initiatives to address unmet needs and to maximise impact in biomedical research.
Over the last 6 years, YLD built and supported three research hubs, CRN (Collaborative Research Network), GP2 (Global Parkinson’s Genetics Program) and ARIA Connect (Aligning Research to Impact Autism). The CRN hub has more than 2250 active users and 6756 Research Outputs, including protocols, datasets and lab resources.
We are now excited to share that we started our new joint project: Aligning Discoveries Across Psychedelic Therapies (ADAPT).
Psychedelic research still knows little about how these substances work, how to measure their effects, or who is likely to benefit, while most of the evidence comes from single-lab studies and company-sponsored trials.
ADAPT brings together a consortium of researchers to establish validated tools and methods that reliably measure the behavioural and biological effects of psilocybin, a naturally occurring psychedelic compound that can be found in more than 200 species of mushrooms, among other psychedelics.
By establishing robust and independently validated research methods, ADAPT aims to better understand how psychedelics could cause lasting changes in thinking and behaviour, to advance both preclinical and human research, and to enable future clinical applications to ensure safe, effective therapies.
Our goal at YLD is to support in building a focused, expert-facing collaboration platform for the ADAPT research community, drawing on the foundations and a deep knowledge of their working practices. This hub will help ADAPT to understand when and for whom psychedelics have therapeutic benefits, uncover psychedelics’ mechanisms, and lay the groundwork for responsible, evidence-based therapies. Our team of engineers, designers and product specialists will cover the whole platform build, from the infrastructure and data models underneath to the look and feel of the hub.
We’re looking forward to being part of a project that expands on the collaborative psychedelic research ecosystem to advance discovery and amplify its therapeutic potential.
If you are curious, read more about the success of our ASAP project here: https://www.yld.com/our-work/accelerating-scientific-progress-through-digital-innovation


